A large proportion of patients with high-risk bladder cancer also have renal insufficiency. These patients are not fit enough to receive cisplatin-based chemotherapy based on impaired renal function. This finding is most strikingly seen in the elderly population. We report a case of an elderly male presenting with advanced carcinoma of the bladder and renal dysfunction.
Introduction
Radical cystectomy is the primary treatment modality for patients with muscle-invasive transitional cell carcinoma (TCC) of the bladder. Patients with either extravesical disease or lymph node-positive status, are at high risk for disease recurrence after surgery alone. [1] Perioperative chemotherapy has been used in an attempt to improve disease control and patient survival. The use of cisplatin-based combination neoadjuvant chemotherapy has shown a survival advantage in two large randomized trials and a meta-analysis. [2] [3] [4] One of the requirements to enroll patients in clinical trials exploring perioperative chemotherapy in urothelial carcinoma is the need for adequate renal function. It has long been known that a large proportion of patients with urothelial cancer have impaired renal function [5] due to multiple factors, including medical comorbidities, age-related decline in glomerular filtration rate (GFR), and ureteral obstruction. It has never been systematically explored as to the degree to which impaired renal function limits the use of perioperative cisplatin-based chemotherapy.
A working group of medical oncologists has laid down certain criteria so as to define patients who are not eligible to receive cisplatin, which includes any of the following: the World Health Organization This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com or the Eastern Cooperative Oncology Group (ECOG) performance status >2, creatinine clearance <60 mL/min, Grade 2 or above audiometric hearing loss, Grade 2 or above peripheral neuropathy, or a New York Heart Association Class III or higher heart failure. [6] When cisplatin therapy is contraindicated, carboplatin has been substituted with the benefit of improved tolerability but with the cost of decreased efficacy. [7, 8] 
Case Report
A 72-year-old male presented to a nursing home with complaints of hematuria of 6-month duration. His hemoglobin levels were 9.4 gm%, serum creatinine was 3.97 mg%, and computed tomography showed a well-defined intraluminal mass lesion measuring 48 mm × 38 mm × 41 mm along the left lateral wall involving the left ureteric orifice. Left pelvicalyceal system and left ureter were dilated up to the bladder [ Figures 1 and 2 ]. In view of the raised creatinine and dilated left pelvicalyceal system, the patient underwent left-sided double J stenting.
The patient was referred to our hospital for further management. The serum creatinine persisted to be high at around 3.74 mg%. The patient was prepared for surgery and underwent transurethral resection of bladder tumor. The histopathological opinion was high-grade muscle infiltrating bladder cancer. The clinical stage of the tumor was T3N0M0. The patient was unwilling for any surgical intervention. It was decided to treat the patient with chemoradiation. The patients Karnofsky Performance Score was 70%, and his creatinine clearance was 40 ml./min. Chemotherapy involved gemcitabine 1200 mg on day 1 and day 8, and dose-adjusted carboplatin 190 mg on day 1 of the cycle, and repeated every 21 days. The patient received 6 cycles of chemotherapy and 4500 rads of radiation to the involved region. The patient withstood the chemoradiation well and is on close follow-up. Serum creatinine done at the end of chemotherapy remained at 3.8 mg%.
Discussion
Bladder cancer is the most common malignancy involving the urinary system and one of the most prevalent solid tumors. [9, 10] Urothelial carcinoma, also referred to as TCC, is the most predominant histologic type, and it accounts for approximately 90% of all bladder cancers. [9, 11] Systemic chemotherapy is the standard approach for patients with inoperable locally advanced or metastatic disease. Although response rates are high, the median survival is only approximately 14 months, whereas the 5-year survival rate is approximately 15% with current combination regimens. [12] Cisplatin has been the cornerstone of chemotherapy regimens for TCC. Cisplatin in combination with other antineoplastic agents has been shown to be significantly more effective than cisplatin monotherapy. The regimen consisting of methotrexate, vinblastine, doxorubicin, and cisplatin has consistently achieved overall survival (OS) of patients with advanced TCC of 12-14 months. [13] [14] [15] Stratification according to the Karnofsky Performance Status (KPS) and site of metastases has identified a sizeable proportion of patients who will achieve long-term disease-free survival. Patients with no risk factors (KPS ≥80% and no visceral metastasis) had a median survival time of 33 months and a 33% likelihood of achieving 5-year survival. Cisplatin-based regimens are associated with significant toxicities, including renal, neurologic, myelosuppression, and ototoxicity. Taking into consideration that most patients with advanced bladder cancer are over 60 years of age, preexisting comorbidities preclude the administration of cisplatin. For the aforementioned reasons, approximately 40%-50% of patients with advanced bladder cancer would not be fit enough to receive cisplatin. [16] Renal dysfunction remains the most common reason for cisplatin-ineligibility. Up to 40% of patients with bladder cancer have renal impairment, defined as a creatinine clearance ≤60 ml/min, as calculated by the CockroftGault formula [ Table 1 ]. [16] Renal insufficiency may be secondary to TCC itself, caused by ureteral blockage, prior nephrectomy or, more often, age-related decrease in the GFR. [17] Creatinine levels that are usually related to a creatinine clearance of <60 ml/min are above 1.5 or 1.6 mg/dl. It is better to avoid cisplatin or other nephrotoxic agents whenever treating patients with renal dysfunction.
Carboplatin is the most widely studied agent in patients with TCC bladder with renal insufficiency. It has always been used in combination with other drugs as a means of overcoming intrinsic resistance to chemotherapy. A popular combination has been the use of carboplatin with gemcitabine, given the efficacy of gemcitabine as a single agent in urothelial carcinoma. Bamias et al. [18] evaluated gemcitabinecarboplatin treatment regimen in 34 patients unfit for cisplatin in a Phase II trial. Treatment resulted in an overall response of 24% and a median OS of 9.8 months. Similarly in another study, Linardou et al. [19] administered gemcitabine and carboplatin to 56 chemo-naive patients who were elderly or otherwise deemed unfit for cisplatin-based chemotherapy based on the same aforementioned criteria. Participants in the study had an ECOG performance status of 2-3 (46%) and/or a GFR of 50 ml/min or less (68%). The overall response rate (ORR) was 36%, with a median progression-free survival of 4.8 months and a median OS of 7.2 months. Bellmunt et al. [20] administered the gemcitabine-carboplatin combination to 16 patients considered unfit for cisplatin-based therapy because of creatinine clearance ≤60 ml/min. The ORR was 44%, while the OS was not reported. Paclitaxel has shown the best single-agent activity in TCC. [21] As paclitaxel can be used at full doses even when renal function is impaired, it forms another partner of carboplatin in the treatment of these patients. The paclitaxel-carboplatin combination has shown ORRs of 21%-50%, with a median progression-free survival of 4-7 months and median OS of approximately 9 months. [22] [23] [24] 
Conclusions
TCC of the bladder is the most common malignancy involving the urinary system. Cisplatin is the mainstay of treatment in patients with advanced/metastatic disease. However, a large number of patients with TCC also have associated renal insufficiency, and are, therefore, unfit to receive such chemotherapy. Although 50% of patients with advanced TCC are unfit to receive cisplatin, there is a lack of randomized trials to define the optimal regimen for those with renal impairment. Multiple Phase II studies have demonstrated the feasibility and activity of substituting carboplatin for cisplatin in conjunction with either gemcitabine, taxanes, or multidrug regimens. In addition, biological agents that are not nephrotoxic are currently under study in this setting.
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